Straumann, A; Conus, S; Grzonka, P; Kita, H; Kephart, G; Bussmann, C; Beglinger, C; Smith, D A; Patel, J; Byrne, M; Simon, H-U (2010). Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut, 59(1), pp. 21-30. London: BMJ Publishing Group 10.1136/gut.2009.178558
Full text not available from this repository. (Request a copy)Eosinophilic oesophagitis (EoO) is a clinicopathological condition defined by proton pump inhibitor-refractory oesophageal symptoms combined with oesophageal eosinophilia. The pharmacodynamic effect of mepolizumab (a humanised anti-interleukin-5 monoclonal antibody) in EoO was evaluated.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology |
UniBE Contributor: |
Conus, Sébastien, Simon, Hans-Uwe |
ISSN: |
0017-5749 |
Publisher: |
BMJ Publishing Group |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:09 |
Last Modified: |
05 Dec 2022 14:00 |
Publisher DOI: |
10.1136/gut.2009.178558 |
PubMed ID: |
19828470 |
Web of Science ID: |
000272609800008 |
URI: |
https://boris.unibe.ch/id/eprint/898 (FactScience: 201192) |
Actions (login required)
 |
Edit item |